|
Affiliation |
Faculty of Medicine College Hospital Department of Endocrinology, Metabolism and Diabetes Medicine |
|
Title |
Associate Professor |
|
External Link |
|
YAMAGUCHI Hideki
|
|
|
Degree 【 display / non-display 】
-
博士（医学） ( 1997.3 宮崎医科大学 )
-
医学士 ( 1988.3 宮崎医科大学 )
Research Areas 【 display / non-display 】
-
Life Science / Metabolism and endocrinology / bioactive peptide
Education 【 display / non-display 】
-
Miyazaki Medical College Graduate School, Division of Medicine
1993.4 - 1997.3
Country：Japan
Campus Career 【 display / non-display 】
-
University of Miyazaki Faculty of Medicine School of Medicine Department of Internal Medicine, Hematology, Diabetes, and Endocrinology Associate Professor
2021.10 - Now
-
University of Miyazaki Faculty of Medicine College Hospital The third internal medicine department Miyazaki University Hospital Lecturer
2010.03 - 2021.09
-
University of Miyazaki Faculty of Medicine School of Medicine Internal medicine course nerve breath internal secretion metabolic study field Assistant Professor
2007.04 - 2010.02
-
University of Miyazaki Faculty of Medicine School of Medicine Internal medicine course nerve breath internal secretion metabolic study field Research Assistant
1998.06 - 2007.03
-
宮崎大学 旧組織 宮崎医科大学医学部附属病院 医員
1998.04 - 1998.06
External Career 【 display / non-display 】
-
Baylor College of Medicine Researcher
1999.11 - 2001.10
Professional Memberships 【 display / non-display 】
-
日本甲状腺学会
2002.4
-
日本糖尿病学会
1989.12
-
日本内科学会
1989.4
-
日本内分泌学会
1989.4
-
日本糖尿病協会
0803.1
Papers 【 display / non-display 】
-
Uchida Taisuke, Yamaguchi Hideki, Arimura Yasuji, Nagayama Ayako, Moritaka Kanoko, Inoguchi Yukihiro, Ashida Kenji, Nomura Masatoshi, Nakazato Masamitsu, Shimoda Kazuya
Endocrine Journal advpub ( 0 ) 825 - 832 2023.5
Authorship：Corresponding author Language：English Publishing type：Research paper (scientific journal) Publisher：The Japan Endocrine Society
There is no computed tomography (CT)-based numerical index for predicting Cushing’s syndrome (CS) in patients with adrenal incidentalomas. We tested the hypothesis that the iliopsoas muscle (Ip-M) to visceral fat (V-fat) ratio (IVR) on CT may predict CS in elderly female patients with adrenal tumors. We examined the V-fat area, subcutaneous fat (S-fat) area, Ip-M area, V-fat/S-fat ratio, and IVR at the third lumbar vertebra (L3) level using abdominal CT in female patients aged ≥50 years with cortisol-producing adrenal tumor diagnosed with CS or non-functioning adrenal tumor (NFT) in the derivation cohort. We performed receiver operating characteristic (ROC) analysis to evaluate the diagnostic value of the V-fat/S-fat ratio and IVR for predicting CS. We assessed the usefulness of the IVR in a separate validation cohort. In the derivation cohort, the IVR was significantly lower in the 9 patients with CS than in the 15 patients with NFT (<i>p</i> < 0.001). In ROC analysis with a cut-off value of 0.067, the IVR showed a sensitivity of 100%, specificity of 80.0%, positive likelihood ratio (PLR) of 5.000, and negative likelihood ratio (NLR) of 0.000. The area under the curve was significantly higher for the IVR than for the V-fat/S-fat ratio (0.933 <i>vs.</i> 0.704, respectively, <i>p</i> = 0.036). In 23 patients in the validation cohort, the IVR demonstrated a PLR of 5.714 and an NLR of 0.327. The novel IVR index, based on single-slice CT at the L3 level, predicted CS in elderly female patients with adrenal tumors.
-
Uchida Taisuke, Yamaguchi Hideki, Kushima Chinami, Yonekawa Tadato, Nakazato Masamitsu
Endocrine Journal 67 ( 1 ) 31 - 35 2019.9
Authorship：Lead author Language：English Publishing type：Research paper (scientific journal) Publisher：The Japan Endocrine Society
<p>We report a case of a 47-year-old woman with hypercalcemia 6 months after discontinuation of denosumab. She underwent right mastectomy for breast cancer and had received aromatase inhibitor and denosumab therapy for 5 years. Thirst, appetite loss, and bilateral ankle pain began few months after cessation of denosumab. She was admitted to the hospital for hypercalcemia and hyperthyroidism 6 months after the last dose of denosumab. Laboratory investigations revealed hypercalcemia, normophosphatemia, normal renal function, and elevated levels of fibroblast growth factor 23 (FGF-23). Serum tartrate-resistant acid phosphatase 5b and urine N-terminal cross-linked telopeptide of type I collagen were both elevated, and bone scintigraphy revealed increase of whole bone uptake. Radiological examinations showed no recurrence of breast cancer or tumors that secrete intact PTH or FGF-23. Hypercalcemia, which lasted for 1 month, was refractory to discontinuation of the aromatase inhibitor, normalization of thyroid hormone levels, saline hydration, and calcitonin administration, but was effectively treated with zoledronic acid. Abnormal uptake on bone scintigraphy and ankle pain both resolved a few months after treatment, and hypercalcemia has not recurred in the ensuing 2 years. In conclusion, we found elevated levels of circulating FGF-23 with hypercalcemia following the discontinuation of denosumab. FGF-23 might be a surrogate marker for massive bone resorption triggered by discontinuation of long-term denosumab treatment.</p>
-
Impaired humoral immunity following COVID-19 vaccination in HTLV-1 carriers Reviewed
Kameda T., Utsunomiya A., Otsuka N., Kubuki Y., Uchida T., Shide K., Kamiunten A., Nakano N., Tokunaga M., Miyazono T., Ito Y., Yonekura K., Kawakita T., Akizuki K., Tahira Y., Karasawa M., Hidaka T., Konagata A., Taniguchi N., Nagatomo Y., Kogo F., Shimizu K., Ueno H., Ishizaki J., Takahashi N., Ikei Y., Hidaka M., Yamaguchi H., Shimoda K.
BMC Infectious Diseases 24 ( 1 ) 96 2024.1
Language：English Publishing type：Research paper (scientific journal) Publisher：BMC Infectious Diseases
Background: Whether human T-lymphotropic virus type 1 (HTLV-1) carriers can develop sufficient humoral immunity after coronavirus disease 2019 (COVID-19) vaccination is unknown. Methods: To investigate humoral immunity after COVID-19 vaccination in HTLV-1 carriers, a multicenter, prospective observational cohort study was conducted at five institutions in southwestern Japan, an endemic area for HTLV-1. HTLV-1 carriers and HTLV-1-negative controls were enrolled for this study from January to December 2022. During this period, the third dose of the COVID-19 vaccine was actively administered. HTLV-1 carriers were enrolled during outpatient visits, while HTLV-1-negative controls included health care workers and patients treated by participating institutions for diabetes, hypertension, or dyslipidemia. The main outcome was the effect of HTLV-1 infection on the plasma anti-COVID-19 spike IgG (IgG-S) titers after the third dose, assessed by multivariate linear regression with other clinical factors. Results: We analyzed 181 cases (90 HTLV-1 carriers, 91 HTLV-1-negative controls) after receiving the third dose. HTLV-1 carriers were older (median age 67.0 vs. 45.0 years, p < 0.001) and more frequently had diabetes, hypertension, or dyslipidemia than did HTLV-1-negative controls (60.0% vs. 27.5%, p < 0.001). After the third dose, the IgG-S titers decreased over time in both carriers and controls. Multivariate linear regression in the entire cohort showed that time since the third dose, age, and HTLV-1 infection negatively influenced IgG-S titers. After adjusting for confounders such as age, or presence of diabetes, hypertension, or dyslipidemia between carriers and controls using the overlap weighting propensity score method, and performing weighted regression analysis in the entire cohort, both time since the third dose and HTLV-1 infection negatively influenced IgG-S titers. Conclusions: The humoral immunity after the third vaccination dose is impaired in HTLV-1 carriers; thus, customized vaccination schedules may be necessary for them.
-
日常臨床に潜むFGF23関連低リン血症性くる病・骨軟化症 Invited
古郷 芙未子、内田 泰介、山口 秀樹
宮崎県内科医会誌 95 20 - 24 2023.10
Authorship：Corresponding author Language：Japanese Publishing type：Research paper (scientific journal)
-
Rare solitary pituitary metastasis of maxillary ameloblastic carcinoma: illustrative case. Reviewed
Arikawa S, Watanabe T, Yamaguchi H, Sato Y, Matsumoto F, Yokogami K, Takeshima H
Journal of neurosurgery. Case lessons 6 ( 10 ) 2023.9
Language：English Publishing type：Research paper (scientific journal) Publisher：Journal of Neurosurgery: Case Lessons
BACKGROUND Ameloblastic carcinoma (AC) is a rare odontogenic carcinoma with histological features resembling ameloblastoma. Metastasis to distant organs and direct expansion into the skull base structures are associated with a poor clinical outcome. This rare case of AC metastasis to the pituitary gland presented without local recurrence at the primary focus of the maxilla. OBSERVATIONS A 47-year-old man had a 2-year history of AC in the right maxilla. Computed tomography for his regular checkup incidentally demonstrated pituitary tumor, rapidly growing over 2 months. He presented with the recent onset of panhypopituitarism and visual field defect. Magnetic resonance imaging showed a large, irregularly shaped intrasellar and suprasellar lesion with chiasmal compression. Endoscopic endonasal transsphenoidal surgery was performed for decompression of the optic apparatus to avoid intracranial spread. Histopathology confirmed metastatic AC, and a genetic panel test confirmed BRAF V600E mutation. Stereotactic radiotherapy (SRT) with the CyberKnife system was administered to the residual tumor. Remarkable tumor shrinkage was obtained, and panhypopituitarism was resolved 12 months later. LESSONS A multidisciplinary treatment strategy including maximal safe resection to avoid dissemination in combination with SRT may be crucial for local control with the preservation of pituitary and visual functions in patients with solitary pituitary metastatic AC.
DOI： 10.3171/CASE23264
Books 【 display / non-display 】
-
褐色細胞腫『救急・集中治療』 31巻3号 特集「ICU治療指針」 II
上平 雄大, 山口秀樹（ Role： Contributor）
総合医学社 2919.12
Total pages：770-1277 Responsible for pages：1066-1068 Language：Japanese Book type：Textbook, survey, introduction
-
副甲状腺機能低下症（偽性機能低下症を含む）
内田 泰介, 山口秀樹（ Role： Contributor）
総合医学社 2019.12
Total pages：1011-1277 Responsible for pages：1047-1049 Language：Japanese Book type：Textbook, survey, introduction
-
慢性副腎不全（ステロイド補充療法を含む）
古郷 芙未子, 山口秀樹（ Role： Contributor）
総合医学社 2019.12
Total pages：770-1277 Responsible for pages：1053-1055 Language：Japanese Book type：Textbook, survey, introduction
-
『病気がみえるvol.3』
山口秀樹（ Role： Supervisor (editorial)）
メディックメディア 2019.10
Total pages：339 Responsible for pages：276-322 Language：Japanese Book type：Textbook, survey, introduction
-
Guide book of endocrine and metabolic diaease, anterior pituitary hormones
（ Role： Contributor）
Shindan to Chiryousya 2018.5
Total pages：761 Responsible for pages：198-202 Language：Japanese Book type：Textbook, survey, introduction
MISC 【 display / non-display 】
-
Uchida T., Ueno H., Konagata A., Taniguchi N., Kogo F., Nagatomo Y., Shimizu K., Yamaguchi H., Shimoda K.
Diabetes Therapy 14 ( 6 ) 1075 - 1076 2023.6
Language：English Publishing type：Rapid communication, short report, research note, etc. (scientific journal) Publisher：Diabetes Therapy
-
Periodic Blood Pressure Fluctuations in Undiagnosed Pheochromocytoma Reviewed
Uehira Yudai, Yamaguchi Hideki, Matsumoto Nobuhiro, Nakazato Masamitsu
Internal Medicine 60 ( 3 ) 491 - 492 2021.2
Authorship：Corresponding author Language：Japanese Publishing type：Rapid communication, short report, research note, etc. (scientific journal) Publisher：The Japanese Society of Internal Medicine
-
頭蓋咽頭腫術後による汎下垂体機能低下症ながら副腎皮質ホルモンの補充なしで16年間にわたり日常生活可能であった1症例. Invited
米川忠人、山口秀樹、平野秀治、中里雅光
ACTH RELATED PEPTIDES 29 7 - 9 2018
Language：Japanese Publishing type：Article, review, commentary, editorial, etc. (scientific journal)
-
キスペプチン受容体変異と思春期遅発症 Invited
山口秀樹、米川忠人、清水浩一郎、中里雅光
内分泌・糖尿病・代謝内科 44 ( 1 ) 50 - 56 2017.1
Language：Japanese Publishing type：Article, review, commentary, editorial, etc. (scientific journal)
-
Basedow病治療中に糖尿病性ケトアシドーシスを呈した多腺性自己免疫症候群３型の１例
中里浩子,米川忠人,野田智穂,迫田秀之,上野浩晶,山口秀樹,中里雅光
宮崎県医師会医学会誌 39 ( 1 ) 75 - 79 2015.3
Language：Japanese Publishing type：Article, review, commentary, editorial, etc. (scientific journal) Publisher：宮崎県医師会?
Presentations 【 display / non-display 】
-
Peptidomic identification and biological validation of neuroendocrine regulatory peptide-1 and -2. International conference
Yamaguchi H, Sasaki K, Satomi Y, Shimbara T, Kageyama H, Mondal MS, Toshinai K, Date Y, González LJ, Shioda S, Takao T, Nakazato M, Minamino N
The Endocrine Society’s 90th Annual Meeting (San Francisco.) The Endocrine Society’s
Event date： 2008.6.15 - 2008.6.18
Language：English Presentation type：Oral presentation (general)
Venue：San Francisco.
-
Characterization and localization of novel neuroendocrine regulatory peptides, NERP-1 and -2, in the human plasma and the hypothalamus. International conference
Matsuo T, Yamaguchi H, Kageyama H, Mondal MS, Sasaki K, Shioda S, Minamino N, Nakazato M
The Endocrine Society’s 90th Annual Meeting (San Francisco.) The Endocrine Society’s
Event date： 2008.6.15 - 2008.6.18
Language：English Presentation type：Oral presentation (general)
Venue：San Francisco.
-
双生児を無事出産した未治療先端巨大症の一例
松尾 崇, 山口秀樹, 土持若葉, 米川忠人, 中里雅光
第280回日本内科学会九州地方会 (福岡) 日本内科学会九州地方会
Event date： 2008.1.26
Language：Japanese Presentation type：Oral presentation (general)
Venue：福岡
-
大量デキサメサゾンで抑制されず下垂体微小腫瘤の同定が困難なクッシング病と考えられる一例.
松尾 崇, 山口秀樹, 米川忠人, 中里雅光
第19回間脳・下垂体副腎研究会 (東京) 間脳下・垂体副腎研究会
Event date： 2008.3.29
Language：Japanese Presentation type：Oral presentation (general)
Venue：東京
-
メチラポンにて二次性糖尿病が軽快した腫瘤の同定困難なクッシング病疑いの一例．
松尾 崇, 山口秀樹, 土持若葉, 米川忠人, 中里雅光
第81回日本内分泌学会総会 (青森) 日本内分泌学会
Event date： 2008.5.16 - 2008.5.18
Language：Japanese Presentation type：Poster presentation
Venue：青森
Awards 【 display / non-display 】
-
第1回日本心血管内分泌代謝学会 若手研究奨励賞
1997.12 日本心血管内分泌代謝学会
山口 秀樹
Award type：Award from Japanese society, conference, symposium, etc. Country：Japan
Grant-in-Aid for Scientific Research 【 display / non-display 】
-
新規グラニン由来ペプチドNERP-4の摂食エネルギー・糖代謝機能の検討
2015.04 - 2018.03
科学研究費補助金 基盤研究(C)
Authorship：Principal investigator
新規に同定したグラニン由来ペプチドNERP-4の摂食エネルギー・糖代謝機能の検討を行う
-
新規ペプチドＮＥＲＰおよび新規グラニン由来ペプチドのインスリン分泌制御機能の探索
2011.05 - 2014.03
科学研究費補助金 基盤研究(C)
Authorship：Principal investigator
分泌性ペプチドの網羅的解析にて新たな生理活性ペプチドNERP (NeuroEndocrine Regulatory Peptide, J Biol Chem, 2007)の同定に成功した。中枢での機能解析で、NERP-1とNERP-2がともにバソプレシン分泌を抑制すること、NERP-2のみが摂食を亢進させることを明らかにし、５つの英文誌に報告した。末梢組織においてNERPは膵β細胞でインスリンと共存すること、MIN6細胞やマウス摘出下垂体を用いた予備実験でインスリン分泌促進作用を有することが明らかとなった（未投稿）。NERPの膵作用機構の解明と、網羅的ペプチド解析時に同定したNERP以外のグラニン由来候補ペプチドのインスリン分泌促進活性の探索を行い、生体内分子を利用した新たな糖尿病治療法の開発研究を実施する。
Committee Memberships 【 display / non-display 】
-
日本糖尿病学会 九州支部評議員
2011.4
Committee type：学協会
Social Activities 【 display / non-display 】
-
糖尿病週間での無料検診
2005.11 - Now
糖尿病週間での宮崎県無料検診に参加している。
-
糖尿病サマーキャンプへの参加
2003.7 - 2008.7
小中高生の糖尿病患者さんを対象としたサマーキャンプにボランティアで参加している。